Accele Biopharma

Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company focused on developing orally active drugs that enhance the effectiveness of existing antibiotics. Founded in 2009, the company operates laboratories in Oklahoma and North Carolina, where it synthesizes compounds aimed at restoring or increasing the potency of antibiotics such as Colistin, polymyxins, carbapenems, aminoglycosides, and fluoroquinolones against gram-negative bacteria. Additionally, Synereca's portfolio includes prototypic RecA inhibitors designed to target a variety of pathogenic bacteria, including E. coli, which are responsible for infections in the lungs, urinary tract, and skin, as well as other dangerous gram-positive and gram-negative pathogens.

Pamlico Biopharma, Inc. is engaged in the development of fully-human monoclonal antibody therapeutics aimed at addressing human pathogens, cancer, and autoimmune diseases. Headquartered in Oklahoma City, the company focuses on innovative solutions for severe pneumonia caused by Streptococcus pneumoniae. Its lead program is centered on a monoclonal antibody cocktail designed to combat this infection, along with a companion point-of-care diagnostic targeting three serotypes responsible for over 40% of these cases. Founded on technologies from the Oklahoma Medical Research Foundation and Emory University, Pamlico Biopharma is currently involved in preclinical activities and is expected to advance to clinical trials in the near future.

Synereca Pharmaceuticals, Inc. is a research-stage biopharmaceutical company focused on developing orally active drugs that enhance the effectiveness of existing antibiotics. Founded in 2009, the company operates laboratories in Oklahoma and North Carolina, where it synthesizes compounds aimed at restoring or increasing the potency of antibiotics such as Colistin, polymyxins, carbapenems, aminoglycosides, and fluoroquinolones against gram-negative bacteria. Additionally, Synereca's portfolio includes prototypic RecA inhibitors designed to target a variety of pathogenic bacteria, including E. coli, which are responsible for infections in the lungs, urinary tract, and skin, as well as other dangerous gram-positive and gram-negative pathogens.

Otologic Pharmaceutics, Inc. is a company committed to developing treatments for acute hearing loss to reduce the development of permanent hearing disorders. OPI’s lead program HPN1010, an oral medication to treat acute hearing loss, will enter clinical trials in 2014. Initial research focuses on Noise Induced Hearing Loss. We will continue to work to expand the applicability of HPN1010 to treat hearing loss from other causes, such as Cisplatin Induced Hearing loss.